Interaction between
Sparsentan
and
Tucatinib
Major
Metabolism
Basic Information
| ID | DDInter2048 and DDInter1891 |
| Interaction | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and effects of sparsentan, which is primarily metabolized by the isoenzyme. |
| Management | Coadministration of sparsentan with potent CYP450 3A4 inhibitors should be avoided. If concomitant use of a potent CYP450 3A4 inhibitor is considered to be clinically necessary, treatment with sparsentan should be interrupted. After discontinuation of the potent CYP450 3A4 inhibitor, sparsenten may be resumed, via careful dose titration as recommended by the manufacturer. |
| References | [1] "Product Information. Filspari (sparsentan)." Travere Therapeutics Inc. (2023): |
| Alternative for Sparsentan | - |
| Alternative for Tucatinib |
L01E
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.